| Drug Name | Active Ingred | Mfr | Indication | Approval Date |
AHFS Class | NDA Chem Type* |
Appl No |
|---|---|---|---|---|---|---|---|
| Arymo ER® | morphine sulfate | Egalet | severe pain requiring daily, around-the-clock, long-term opioid treatment | 2017/01/09 | 28:08.08 - Opiate Agonists | 5S | 208603 |
| Nitrous Oxide | nitrous oxide | Matheson Tri-Gas | general anesthesia; analgesia | 2017/01/09 | 28:04.16 - Inhalation Anesthetics | 209989 | |
| Esbriet® | pirfenidone | Genentech | idiopathic pulmonary fibrosis (IPF) | 2017/01/11 | 48:02 - Antifibrotic Agents | 3S | 208780 |
| Vantrela ER® | hydrocodone | Teva | pain | 2017/01/17 | 28:08.08 - Opiate Agonists | 3S | 207975 |
| Rhofade® | oxymetazoline | Allergan | persistent facial erythema associated with rosacea | 2017/01/18 | 84:92 - Skin and Mucous Membrane Agents, Misc | 10S | 208552 |
| Trulance® | plecanatide | Synergy | chronic idiopathic constipation (CIC) | 2017/01/19 | 56:92 - GI Drugs, Miscellaneous | 1S | 208745 |
| Tepadina® | thiotepa | Adienne SA | reduce risk of graft rejection; adenocarcinoma of the breast or ovary; superficial papillary carcinoma of the urinary bladder; controlling intracavitary effusions | 2017/01/26 | 10:00 - Antineoplastic Agents | 5S | 208264 |
| ArmonAirTM Respiclick® | fluticasone propionate | Teva | asthma | 2017/01/27 | 68:04 - Adrenals | 5S | 208798 |
| AirDuoTM Respiclick® | fluticasone propionate; salmeterol | Teva | asthma | 2017/01/27 | 68:04 - Adrenals; 12:12.08.12 - Selective beta-2-Adrenergic Agonists | 4S | 208799 |
| Corphedra® | ephedrine | Par | anesthesia-induced hypotension | 2017/01/27 | 12:12.12 - alpha- and beta-Adrenergic Agonists | 5S | 208943 |
| Parsabiv® | etelcalcetide | Kai | secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis | 2017/02/07 | 92:92 - Other Miscellaneous Therapeutic Agents | 1S | 208325 |
| Emflaza® | deflazacort | Marathon | Duchenne muscular dystrophy (DMD) | 2017/02/09 | 68:04 - Adrenals | 1P | 208684 |
| Siliq® | brodalumab | Valeant | plaque psoriasis | 2017/02/15 | 84:92 - Skin and Mucous Membrane Agents, Misc | 761032 | |
| Qtern® | dapagliflozin; saxagliptin | AstraZeneca | type 2 diabetes mellitus | 2017/02/27 | 68:20.18 - SGLT-2 Inhibitors; 68:20.05 - DPP-4 Inhibitors | 4S | 209091 |
| Xermelo® | telotristat ethyl | Lexicon Pharma | carcinoid syndrom diarrhea | 2017/02/28 | 56:08 - Antidiarrhea Agents | 1S | 208794 |
| Noctiva® | desmopressin acetate | Serenity | nocturnal polyuria | 2017/03/03 | 68:28 - Pituitary | 5S | 201656 |
| Kisqali® | ribociclib | Novartis | HR+/HER2- advanced or metastatic breast cancer | 2017/03/13 | 10:00 - Antineoplastic Agents | 1P | 209092 |
| Xadago® | safinamide | Newron | Parkinson's disease | 2017/03/21 | 28:36.32 - Monoamine Oxidase B Inhibitors | 1S | 207145 |
| Symproic® | naldemedine | Shionogi | opioid-induced constipation (OIC) | 2017/03/23 | 56:92 - GI Drugs, Miscellaneous | 1S | 208854 |
| Bavencio® | avelumab | EMD Serono | metastatic Merkel cell carcinoma (MCC) | 2017/03/23 | 10:00 - Antineoplastic Agents | 761049 | |
| Zejula® | niraparib | Tesaro | epithelial ovarian, fallopian tube, or primary peritoneal cancer | 2017/03/27 | 10:00 - Antineoplastic Agents | 1P | 208447 |
| Dupixent® | dupilumab | Regeneron | moderate-to-severe eczema (atopic dermatitis) | 2017/03/28 | 84:92 - Skin and Mucous Membrane Agents, Misc | 761055 | |
| Ocrevus® | ocrelizumab | Genentech | relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) | 2017/03/28 | 92:20 - Immunomodulatory Agents | 761053 | |
| Odactra® | house dust mites (HDM) allergen extract | MSD | HDM-induced allergic rhinitis | 2017/03/01 | 80:02 - Allergenic Extracts | 125592 | |
| Austedo® | deutetrabenazine | Teva | Huntington's chorea, tardive dyskinesia | 2017/04/03 | 28:92 - Central Nervous System Agents, Misc | 1S | 208082 |
| Ingrezza® | valbenazine | Neurocrine Biosciences | tardive dyskinesia | 2017/04/11 | 28:92 - Central Nervous System Agents, Misc | 1P | 209241 |
| Roxybond® | oxycodone | Inspirion | pain | 2017/04/20 | 28:08.08 - Opiate Agonists | 5P | 209777 |
| Renflexis® | infliximab-abda | Samsung Bioepsis | Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis | 2017/04/21 | 92:36 - Disease-modifying Antirheumatic Drugs | 761054 | |
| Xatmep® | methotrexate | Silvergate | acute lymphoblastic leukemia (ALL) in pediatric patients; active polyarticular juvenile idiopathic arthritis (pJIA) | 2017/04/25 | 10:00 - Antineoplastic Agents | 3S | 208400 |
| Brineura® | cerliponase alfa | Biomarin | indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency. | 2017/04/27 | 44:00 - Enzymes | 761052 | |
| Rydapt® | midostaurin | Novartis | acute myeloid leukemia (AML) that is FLT3 mutation-positive; aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia | 2017/04/28 | 10:00 - Antineoplastic Agents | 1P | 207997 |
| Tymlos® | abaloparatide | Radius | postmenopausal women with osteoporosis at high risk for fracture | 2017/04/28 | 68:24 - Parathyroid | 1/4S | 208743 |
| Alunbrig® | brigatinib | Ariad | anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) | 2017/04/28 | 10:00 - Antineoplastic Agents | 1P | 208772 |
| Imfinzi® | durvalumab | AstraZeneca | locally advanced or metastatic urothelial carcinoma | 2017/05/01 | 10:00 - Antineoplastic Agents | 761069 | |
| Steritalc® | talc | Novatech | decrease the recurrence of malignant pleural effusions and pneumothorax | 2017/05/01 | 24:16 - Sclerosing Agents | 5S | 205555 |
| Kisqali® Femara® Co-Pack | letrozole; ribociclib | Novartis | hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer | 2017/05/04 | 10:00 - Antineoplastic Agents | 4S | 209935 |
| Radicava® | edaravone | MT Pharma | amyotrophic lateral sclerosis (ALS) | 2017/05/05 | 28:92 - Central Nervous System Agents, Miscellaneous | 1 | 209176 |
| Minolira® | minocycline hydrochloride | Dr Reddy's | moderate to severe acne vulgaris | 2017/05/08 | 84:92 - Skin and Mucous Membrane Agents, Misc | 5S | 209269 |
| Jadenu® | deferasirox | Novartis | chronic iron overload | 2017/05/08 | 64:00 - Heavy Metal Antagonists | 5S | 207968 |
| Kevzara® | sarilumab | Sanofi | adult rheumatoid arthritis | 2017/05/23 | 92:36 - Disease-modifying Antirheumatic Drugs | 761037 | |
| Zerviate® | cetirizine hydrochloride | Nicox | ocular itching associated with allergic conjunctivitis | 2017/05/30 | 52:02 - Antiallergic Agents | 3P | 208694 |
| Rebinyn® | factor IX (recombinant), glycoPEGylated (INN: nonacog beta pegol) | Novo Nordisk | hemophilia B for on-demand treatment and control of bleeding episodes and for perioperative management of bleeding | 2017/05/31 | 20:28.16 - Hemostatics | 125611 | |
| Gleolan® | aminolevulinic acid oral solution | NX | optical imaging | 2017/06/06 | 36:68 - Roentgenographic and Other Imaging Agents | 3P | 208630 |
| Fibryna® | fibrinogen (human) | Octapharma | afibrinogenemia and hypofibrinogenemia | 2017/06/07 | 20:28.16 - Hemostatics | 125612 | |
| Baxdela® | delafloxacin | Melinta | acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria | 2017/06/19 | 8:12.18 - Quinolones | 1S | 208610 |
| Haegarda® | C1 esterase inhibitor (human) | CSL Behring | prophylaxis of hereditary angioedema (HAE) | 2017/06/22 | 92:32 - Complement Inhibitors | 125606 | |
| Bevyxxa® | betrixaban | Portola | prophylaxis of venous thromboembolism (VTE) | 2017/06/23 | 20:12.04.14 - Direct Factor Xa Inhibitors | 1S | 208383 |
| Triptodur® Kit | triptorelin | Arbor | central precocious puberty | 2017/06/29 | 68:18 - Gonadotropins | 5S/O | 208956 |
| Endari® | L-glutamine | Emmaus | reduce acute complications associated with sickle cell disease | 2017/07/07 | 92:92 - Other Miscellaneous Therapeutic Agents | 5S | 208587 |
| Tremfya® | guselkumab | Janssen | moderate-to-severe plaque psoriasis | 2017/07/13 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | 761061 | |
| Zypitamag® | pitavastatin magnesium | Zydus | primary hyperlipidemia or mixed dyslipidemia | 2017/07/14 | 24:06.08 - HMG-CoA Reductase Inhibitors | 2S | 208379 |
| Nerlynx® | neratinib | Puma | early stage HER2-overexpressed/amplified breast cancer | 2017/07/17 | 10:00 - Antineoplastic Agents | 1S | 208051 |
| Vosevi® | sofosbuvir; velpatasvir; voxilaprevir | Gilead | hepatitis C virus (HCV) infection | 2017/07/18 | 8:18.40.16 - HCV Polymerase Inhibitors | 1/4P | 209195 |
| Lusduna® | insulin glargine | Merck Sharp Dohme | type 1 or 2 diabetes mellitus | 2017/07/19 | 68:20.08 - Insulins | 5S | 208722 |
| Nityr® | nitisinone | Cycle Pharms | hereditary tyrosinemia type 1 (HT-1) | 2017/07/26 | 92:92 - Other Miscellaneous Therapeutic Agents | 5S | 209449 |
| Idhifa® | enasidenib | Celgene | acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation | 2017/08/01 | 10:00 - Antineoplastic Agents | 1P | 209606 |
| Vyxeos® | daunorubicin liposomal; cytarabine | Celator | therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) | 2017/08/03 | 10:00 - Antineoplastic Agents | 4S | 209401 |
| Mavyret® | glecaprevir; pibrentasvir | Abbvie | hepatitis C virus (HCV) infection | 2017/08/03 | 8:18.40.20 - HCV Protease Inhibitors; 8:18.40.24 - HCV Replication Complex Inhibitors | 1,4P | 209394 |
| Carospir® | spironolactone | CMP | heart failure, hypertension, edema | 2017/08/04 | 24:32.20 - Mineralocorticoid (Aldosterone) Receptor Antagonists | 3S | 209478 |
| Nikita® | pitavastatin | Lupin | dyslipidemias | 2017/08/04 | 24:06.08 - HMG-CoA Reductase Inhibitors | 2S | 209478 |
| Lynparza® | olaparib | AstraZeneca | ovarian cancer | 2017/08/17 | 10:00 - Antineoplastic Agents | 3P | 208558 |
| Drax Exametazime | drax exametazime | Jubilant | leukocyte (white blood cell) labeled scintigraphy as an adjunct in the localization of intraabdominal infection and inflammatory bowel disease | 2017/08/17 | 36:68 - Roentgenography | 5S | 208870 |
| Besponsa® | inotuzumab | Wyeth | relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) | 2017/08/17 | 10:00 - Antineoplastic Agents | 1P/O | 761040 |
| Duzallo® | lesinurad; allopurinol | Ardea | hyperuricemia associated with gout | 2017/08/18 | 40:40 - Uricosuric Agents; 92:16 - Antigout Agents | 4S | 209203 |
| Kedrab® | rabies immune globulin (human) | Kamada | post-exposure prophylaxis of rabies infection | 2017/08/23 | 80:04 - Antitoxins and Immune Globulins | 125613 | |
| Gocovri® | amantadine | Adamas | dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy | 2017/08/24 | 28:36.04 - Adamantanes | 3S/O | 208944 |
| Cyltezo® | adalimumab-adbm | Boehringer Ingelheim | rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulerative colitis (UC), plaque psoriasis (Ps) | 2017/08/25 | 92:36 - Disease-modifying Antirheumatic Drugs, 92:20 - Immunomodulatory Agents, 56:92 - GI Drugs, Misc | 761058 | |
| benznidazole | benznidazole | Chemo Research | Chagas disease (American trypanosomiasis) | 2017/08/29 | 8:30.92 - Antiprotozoals, Misc | 1P/O | 209570 |
| Vabomere® | meropenem; vaborbactam | Rempex | complicated urinary tract infections (cUTI) | 2017/08/29 | 8:12.07.08 - Carbapenems | 1/4P | 209776 |
| Kymriah® | tisagenlecleucel | Novartis | B-cell precursor acute lymphoblastic leukemia (ALL) | 2017/08/30 | 26:12 - Gene Therapy (new class); 10:00 - Antineoplastic Agents | 125646 | |
| Mylotarg® | gemtuzumab | Wyeth | acute myeloid leukemia (CD33+ AML) | 2017/09/01 | 10:00 - Antineoplastic Agents | 761060 | |
| Aliqopa® | copanlisib | Bayer | relapsed follicular lymphoma (FL) | 2017/09/14 | 10:00 - Antineoplastic Agents | 1P/O | 209936 |
| Mvasi® | bevacizumb-awwb | Amgen | metastatic colorectal cancer; non-squamous non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; cervical cancer | 2017/09/14 | 10:00 - Antineoplastic Agents | 761028 | |
| Adzenys® ER | amphetamine | Neos | attention deficit hyperactivity disorder (ADHD) | 2017/09/15 | 28:20.04 - Amphetamines | 3S | 204325 |
| Solosec® | secnidazole | Symbiomix | bacterial vaginosis | 2017/09/15 | 8:30.92 - Antiprotozoals, Misc | 1P | 209363 |
| Xhance® | fluticasone propionate | Optnose | rhinitis | 2017/09/18 | 52:08.08 - Corticosteroids | 5S | 209022 |
| Trelegy Ellipta® | fluticasone furoate; umeclidinium; vilanterol | GlaxoSmithKline | chronic obstructive pulmonary disease (COPD) | 2017/09/18 | 68:04 - Adrenals; 12:08.08 - Antimuscarinics/Antispasmodics; 12:12.08.12 - Selective beta-2-Adrenergic Agonists | 5S | 209022 |
| Clorotekal® | chloroprocaine | Sintetica | spinal anesthesia | 2017/09/26 | 72:00 - Local Anesthetics | 5S | 208791 |
| Verzenio® | abemaciclib | Eli Lilly | HR+,HER2- advanced or metastatic breast cancer | 2017/09/28 | 10:00 - Antineoplastic Agents | 1S | 208716 |
| Fiasp® | insulin aspart | Novo Nordisk | diabetes | 2017/09/29 | 68:20.08 - Insulins | 5S | 208751 |
| Ascor® | ascorbic acid | McGuff | scurvy | 2017/10/02 | 88:12 - Vitamin C | 7S | 209112 |
| Zilretta® | triamcinolone acetonide | Flexion | osteoarthritis knee pain | 2017/10/06 | 68:04 - Adrenals | 5S | 208845 |
| Lyrica CR® | pregabalin | Pfizer | neuropathic pain associated with diabetic peripheral neuropathy (DPN); postherpetic neuralgia (PHN) | 2017/10/11 | 28:12.92 - Anticonvulsants, Misc; 28:40 - Fibromyalgia Agents; 28:08.92 - Analgesics and Antipyretics, Misc | 5S | 209501 |
| Yescarta® | axicabtagene ciloleucel | Kite | certain types of non-Hodgkin lymphoma (NHL) | 2017/10/18 | 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents | 125643 | |
| Shingrix® | zoster vaccine recombinant | GSK | shingles (herpes zoster) vaccine | 2017/10/20 | 80:12 - Vaccines | 125614 | |
| Calquence® | acalabrutinib | Acerta | mantle cell lymphoma (MCL) | 2017/10/31 | 10:00 - Antineoplastic Agents | 1P | 210259 |
| Vyzulta® | latanoprostene bunod | Valeant | open-angle glaucoma or ocular hypertension | 2017/11/02 | 52:40.28 - Prostaglandin Analogs | 1 | 207795 |
| Prevymis® | letermovir | MSD | prophylaxis of cytomegalovirus (CMV) infection | 2017/11/08 | 8:18.92 - Antivirals, Misc | 1 | 209939 |
| Heplisav-B® | hepatitis B vaccine, recombinant | Dynavax | prevention of hepatitis B (HBV) infection | 2017/11/09 | 80:12 - Vaccines | 125428 | |
| Cinvanti® | aprepitant | Heron | nausea and vomiting associated with chemotherapy | 2017/11/09 | 56:22.32 - Neurokinin-1 (NK1) Receptor Antagonists | 3 | 209296 |
| Abilify Mycite® | aripiprazole with ingestible event marker (IEM) | Otsuka | schizophrenia, bipolar disorder, major depressive disorder | 2017/11/13 | 28:16.08.04 - Atypical Antipsychotics | 4 | 207202 |
| Fasenra® | benralizumab | AstraZeneca | add-on maintenance of severe asthma | 2017/11/14 | 48:10.20 - Interleukin Antagonists | 761070 | |
| Mepsevii® | vestronidase alfa-vjbk | UltraGenyx | mucopolysaccharidosis type VII (MPS VII, Sly syndrome) | 2017/11/15 | 44:00 - Enzymes | 761047 | |
| Hemlibra® | emicizumab-kxwh | Genentech | hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors | 2017/11/16 | 20:28.16 - Hemostatics | 761083 | |
| Juluca® | dolutegravir; rilpivirine | Viiv | HIV-1 infection | 2017/11/21 | 8:18.08.12 - HIV Integrase Inhibitors; 8:18.08.16 - HIV Nonnucleoside Reverse Transcriptase Inhibitors | 4P | 210192 |
| Impoyz® | clobetasol propionate | Promius | moderate-to-severe plaque psoriasis | 2017/11/28 | 84:06.08 - Corticosteroids | 5S | 209483 |
| Clenpiq® | sodium picosulfate; magnesium oxide; anhydrous citrix acid | Ferring | colon preparation for colonoscopy | 2017/11/28 | 56:12 - Cathartics and Laxatives | 3S | 209589 |
| Sublocade® | buprenorphine | Indivior | moderate to severe opioid use disorder | 2017/11/30 | 28:08.12 - Opiate Partial Agonists | 3P | 209819 |
| Ogivri® | trastuzumab-dkst | Mylan | HER2-overexpressing breast cancer and metastatic gastric/gastroesophageal junction adenocarcinoma | 2017/12/01 | 10:00 - Antineoplastic Agents | 761074 | |
| Lonhala Magnair® | glycopyrrolate | Sunovion | long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) | 2017/12/05 | 12:08.08 - Antimuscarinics/Antispasmodics | 3/4S | 208437 |
| Ozempic® | semaglutide | Novo Nordisk | type 2 diabetes mellitus | 2017/12/05 | 68:20.06 - Incretin Mimetics | 1S | 209637 |
| Xepi® | ozenoxacin | Ferrer | topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes | 2017/12/11 | 84:04.04 - Antibacterials | 1S | 208945 |
| Admelog® | insulin lispro | Sanofi Aventis | diabetes mellitus | 2017/12/11 | 68:20.08 - Insulins | 5S | 209196 |
| Tydemy® | drospirenone; ethinyl estradiol; levomefolate calcium | Lupin | birth control | 2017/12/12 | 68:12 - Contraceptives | 205948 | |
| Ixifi® | infliximab-qbtx | Pfizer | Crohn's disease; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; plaque psoriasis | 2017/12/13 | 92:20 - Immunomodulatory Agents; 92:36 - Disease-modifying Antirheumatic Drugs | 761072 | |
| Altafluor Benox® | fluorescein; benoxinate | Altaire | tonometry, gonioscopy | 2017/12/14 | 36:58 - Ocular Disorders; 52:16 - Local Anesthetics | 4P | 208582 |
| Eskata® | hydrogen peroxide | Aclaris | seborrheic keratoses | 2017/12/14 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous (was 84:28) | 5S | 209305 |
| Goprelto® | cocaine | Genus | local anesthesia of the nasal cavities | 2017/12/14 | 52:16 - Local Anesthetics | 5S | 209963 |
| Rhopressa® | netarsudil | Aerie | open-angle glaucoma or ocular hypertension | 2017/12/18 | 52:40.92 - Antiglaucoma Agents, Miscellaneous | 1S | 208254 |
| Prexxartan® | valsartan | Carmel | hypertension, heart failure, stable left ventricular failure or left ventricular dysfunction following myocardial infarction | 2017/12/19 | 24:32.08 - Angiotensin II Receptor Antagonists | 3S | 209139 |
| Steglatro® | ertugliflozin | Merck Sharp Dohme | type 2 diabetes mellitus | 2017/12/19 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors | 1S | 209803 |
| Steglujan® | ertugliflozin; sitagliptin | Merck Sharp Dohme | type 2 diabetes mellitus | 2017/12/19 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; 68:20.05 - Dipeptidyl Peptidase-4 (DPP-4) Inhibitors | 1/4S | 209805 |
| Stegluromet® | ertugliflozin; metformin | Merck Sharp Dohme | type 2 diabetes mellitus | 2017/12/19 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; 68:20.04 - Biguanides | 1/4S | 209805 |
| Luxturna® | voretigene neparvovec-rzyl | Spark Therapeutics | biallelic RPE65 mutation-associated retinal dystrophy | 2017/12/19 | 26:12 - Gene Therapy | 125610 | |
| Macrilen® | macimorelin | Aeterna Zentaris | diagnosis of adult growth hormone deficiency | 2017/12/20 | 36:66 - Pituitary | 1S | 205598 |
| Siklos® | hydroxyurea | Addmedica | sickle cell anemia with recurrent moderate to severe painful crises in pediatric patients | 2017/12/21 | 10:00 - Antineoplastic Agents | 3P | 208843 |
| Giapreza® | angiotensin II | La Jolla | increase blood pressure in septic shock | 2017/12/21 | 68:44 - Renin-Angiotensin-Aldosterone System (RAAS) (new class) | 1P | 209360 |
| Lumify® (OTC) | brimonidine | Bausch and Lomb | redness due to minor eye irritations | 2017/12/22 | 52:40.04 - alpha-Adrenergic Agonists | 5/8S | 208144 |
| AHFS Class | Change Date | Change Description |
|---|---|---|
| 68:24 - Parathyroid and Antiparathyroid Agents | 2017/08/10 | Rename class from Parathyroid |
| 68:24.04 - Antiparathyroid Agents | 2017/08/10 | New subclass |
| 68:24.08 - Parathyroid Agents | 2017/08/10 | New subclass |
| 26:00 - Cellular and Gene Therapy | 2017/09/08 | Rename class from Cellular Therapy |
| 26:04 - Cellular Therapy | 2017/09/08 | New subclass |
| 26:12 - Gene Therapy | 2017/09/08 | New subclass |
| 68:18 - Gonadotropins and Antigonadotropins | 2017/09/15 | Rename class from Gonadotropins |
| 68:18.04 - Antigonadotropins | 2017/09/15 | New subclass |
| 68:18.08 - Gonadotropins | 2017/09/15 | New subclass |
| 68:16.08 - Antiestrogens | 2017/09/20 | Revived old class that was retired in 2007 |
| 92:18 - Antisense Oligonucleotides | 2017/09/20 | New subclass |
| 28:56 - Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors | 2017/10/16 | New subclass |
| 84:06.08 - Corticosteroids | 2017/12/15 | New subclass |
| 84:06.20 - Nonsteroidal Anti-inflammatory Agents | 2017/12/15 | New subclass |
| 84:06.92 - Anti-inflammatory Agents, Miscellaneous | 2017/12/15 | New subclass |
| 68:44 - Renin-Angiotensin-Aldosterone System (RAAS) | 2017/12/21 | New subclass |
| Drug Name(s) | Active Ingred | Change Date |
Old AHFS Class | New AHFS Class |
|---|---|---|---|---|
| Fortical®, Miacalcin® | calcitonin | 2017/08/10 | 68:24 - Parathyroid | 68:24.04 - Antiparathyroid Agents |
| Sensipar® | cinacalcet | 2017/08/10 | 92:92 - Other Miscellaneous Therapeutic Agents | 68:24.04 - Antiparathyroid Agents |
| Parsabiv® | etelcalcetide | 2017/08/10 | 92:92 - Other Miscellaneous Therapeutic Agents | 68:24.04 - Antiparathyroid Agents |
| Tymlos® | abaloparatide | 2017/08/10 | 68:24 - Parathyroid | 68:24.08 - Parathyroid Agents |
| Forteo® | teriparatide | 2017/08/10 | 68:24 - Parathyroid | 68:24.08 - Parathyroid Agents |
| Natpara® | parathyroid hormone | 2017/08/10 | 68:24 - Parathyroid | 68:24.08 - Parathyroid Agents |
| Laviv® | azficel-T | 2017/09/08 | 26:00 - Cellular Therapy | 26:04 - Cellular Therapy |
| Provenge® | sipuleucel-T | 2017/09/08 | 26:00 - Cellular Therapy | 26:04 - Cellular Therapy |
| Cetrotide® | cetrorelix | 2017/09/15 | 92:40 - Gonadotropin-releasing Hormone Antagonists | 68:18.04 - Antigonadotropins |
| Firmagon® | degarelix | 2017/09/15 | 10:00 - Antineoplastic Agents | 68:18.04 - Antigonadotropins; 10:00 - Antineoplastic Agents |
| Antagon® | ganirelix | 2017/09/15 | 92:40 - Gonadotropin-releasing Hormone Antagonists | 68:18.04 - Antigonadotropins |
| Ovidrel® | choriogonadotropin alfa | 2017/09/15 | 68:18 - Gonadotropins | 68:18.08 - Gonadotropins |
| Novarel®, Pregnyl® | gonadotropin, chorionic | 2017/09/15 | 68:18 - Gonadotropins | 68:18.08 - Gonadotropins |
| Zoladex® | goserelin | 2017/09/15 | 10:00 - Antineoplastic Agents | 68:18.08 - Gonadotropins; 10:00 - Antineoplastic Agents |
| Vantas® | histrelin | 2017/09/15 | 10:00 - Antineoplastic Agents | 68:18.08 - Gonadotropins; 10:00 - Antineoplastic Agents |
| Eligard®, Lupron®, Lupron® Depot | leuprolide | 2017/09/15 | 10:00 - Antineoplastic Agents | 68:18.08 - Gonadotropins; 10:00 - Antineoplastic Agents |
| Lupaneta® | leuprolide; norethindrone | 2017/09/15 | 10:00 - Antineoplastic Agents; 68:32 - Progestins | 68:18.08 - Gonadotropins; 68:32 - Progestins; 10:00 - Antineoplastic Agents |
| Luveris® | lutropin alfa | 2017/09/15 | 68:18 - Gonadotropins | 68:18.08 - Gonadotropins |
| Synarel® | nafarelin | 2017/09/15 | 68:18 - Gonadotropins | 68:18.08 - Gonadotropins |
| Trelstar®, Triptodur® | triptorelin | 2017/09/15 | 10:00 - Antineoplastic Agents | 68:18.08 - Gonadotropins; 10:00 - Antineoplastic Agents |
| Megace® | megestrol | 2017/09/15 | 10:00 - Antineoplastic Agents | 68:32 - Progestins; 10:00 - Antineoplastic Agents |
| Nolvadex® | tamoxifen | 2017/09/15 | 10:00 - Antineoplastic Agents | 68:16.12 - Estrogen Agonist-Antagonists; 10:00 - Antineoplastic Agents |
| Fareston® | toremifene | 2017/09/15 | 10:00 - Antineoplastic Agents | 68:16.12 - Estrogen Agonist-Antagonists; 10:00 - Antineoplastic Agents |
| Arimidex® | anastrozole | 2017/09/20 | 10:00 - Antineoplastic Agents | 68:16.08 - Antiestrogens; 10:00 - Antineoplastic Agents |
| Aromsin® | exemestane | 2017/09/20 | 10:00 - Antineoplastic Agents | 68:16.08 - Antiestrogens; 10:00 - Antineoplastic Agents |
| Femara® | letrozole | 2017/09/20 | 10:00 - Antineoplastic Agents | 68:16.08 - Antiestrogens; 10:00 - Antineoplastic Agents |
| Kisqali®/Femara® Co-Pack (combination) | letrozole; ribociclib | 2017/09/20 | 10:00 - Antineoplastic Agents; 10:00 - Antineoplastic Agents | 68:16.08 - Antiestrogens; 10:00 - Antineoplastic Agents |
| Exondys 51® | eteplirsen | 2017/09/21 | 92:92 - Other Miscellaneous Therapeutic Agents | 92:18 - Antisense Oligonucleotides |
| Spinraza® | nusinersen | 2017/09/21 | 92:92 - Other Miscellaneous Therapeutic Agents | 92:18 - Antisense Oligonucleotides |
| Kynamro® | mipomersen | 2017/09/21 | 24:06.92 - Antilipemic Agents, Misc | 24:06.92 - Antilipemic Agents, Misc; 92:18 - Antisense Oligonucleotides |
| Austedo® | deutetrabenazine | 2017/10/16 | 28:92 - CNS Agents, Misc | 28:56 - Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors |
| Xenazine® | tetrabenazine | 2017/10/16 | 28:92 - CNS Agents, Misc | 28:56 - Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors |
| Ingrezza® | valbenazine | 2017/10/16 | 28:92 - CNS Agents, Misc | 28:56 - Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors |
| Eucrisa® | crisaborole | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.92 - Anti-inflammatory Agents, Miscellaneous |
| Aclovate® | alclometasone | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Cyclocort® | amcinonide | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Alphatrex®, Betatrex®, Beta-Val®, Diprolene®, Luxiq®, Maxivate® | betamethasone | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Clobevate®, Clobex®, Cormax®, Embeline®, Olux®, Temovate® | clobetasol | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Cloderm® | clocortolone | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Desonate®, DesOwen®, Verdeso® | desonide | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Topicort® | desoximetasone | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Psorcon® | diflorasone | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Capex®, Derma-Smoothe/FS®, Lidex®, Lidex-E®, Synalar®, Synemol® | fluocinolone/fluocinonide | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Cordran® | flurandrenolide | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Halog®, Halog-E® | halcinonide | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Ultravate® | halobetasol | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Ala-Cort®, Anucort-HC®, Anusert-HC®, Anusol-HC®, Cetacort®, Cortizone®, Dermacort®, Lanacort®, Proctocort®, Sarnol-HC®, Texacort®, Westcort® | hydrocortisone | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Elocon® | mometasone | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Dermatop® | prednicarbate | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Aristocort®, Flutex®, Kenalog®, Triacet® | triamcinolone | 2017/12/15 | 84:06 - Anti-inflammatory Agents | 84:06.08 - Corticosteroids |
| Pennsaid®, Solaraze® 3% Gel, Voltaren® 1% Gel | diclofenac sodium | 2017/12/15 | 84:92 - Skin and Mucous Membrane Agents, Misc | 84:06.20 - Nonsteroidal Anti-inflammatory Agents |